Dilated cardiomyopathy (DCM) is a group of etiologically heterogeneous cardiac diseases, all characterized by cardiac enlargement associated with systolic dysfunction and often manifested by congestive heart failure (1) . Although the majority of DCM patients are sporadic cases, apparent family histories can be found in 20%-35% of patients, suggesting that genetic defects or gene abnormalities cause DCM at least in a part of the patients (2) . There are several reports of genetic etiologies of DCM, and they may be classified into at least four groups. (I) abnormalities in the components of cardiac cytoarchitecture, such as mutations in genes for ␣-cardiac actin, desmin, dystrophin, ␦-sarcoglycan, desmoplakin, and plakoglobin (3) (4) (5) (6) (7) (8) ; (II) mutations in the genes for cardiac sarcomere, such as cardiac ␤ myosin heavy chain and cardiac troponin T (9); (III) defects affecting mitochondrial function, such as CPTase II deficiency and mutations in tafazzin gene (10, 11) ; and (IV) defects in components of nuclear envelope, which may participate in signal transduction between the cytoplasm and the nucleus, such as mutations in emerin and lamin A/C (12, 13) . Most of the disease-related mutations are inherited as the autosomal dominant trait (3, 4, 6, 9, 13) , but some mutations show autosomal recessive (7, 8, 10) or X-linked recessive (5, 11, 12) inheritance.
Among these genetic causes, the majority can be classified into the cytoarchitectural abnormalities that may cause abnormal force transmission at the Z-line between the sarcomeres (14) . Several animal models also support this idea; for example, targeted disruption of the genes for muscle LIM protein (MLP) and actininassociated LIM protein (ALP) in mice (15, 16) , and a mutation of the ␦-sarcoglycan gene in hamster (17) result in the development of DCM, although the disease in these animal models is the autosomal recessive trait. The genetic defects or mutations in the disease genes, however, could be identified only in a minor proportion of DCM patients, even if they have apparent family histories, i.e., familial DCM patients. On the other hand, linkage studies suggested a disease locus in each multiplex family with DCM. These linkage studies have so far identified 10 different disease loci (18) , among which only the lamin A/C gene has been revealed to be the causative gene for familial DCM (13) . These observations indicate that there are many other disease genes to be identified for better understanding the molecular pathogenesis of DCM.
Titin, also called connectin, is a giant muscle protein expressed in the cardiac and skeletal muscles, spanning entire half of the sarcomere from Z-line to M-line, and plays a key role in muscle assembly, force transmission at the Z-line, and maintenance of resting tension in I-band region (19) . Titin has been shown to interact with other sarcomeric proteins; T-cap/ telethonin and ␣-actinin at the Z-line region, calpain 3 and obscurin at the I-band region, and myosin binding protein C, calmodulin and again calpain 3 at the M-line region (20) . In addition, a linkage study in a large multiplex family with DCM has mapped a DCM locus on chromosome 2q31 (21) overlapping with the titin gene locus at 2q24.3. These observations suggest that the titin gene is a good candidate of the novel disease gene for DCM, although a preliminary study of heartspecific exons for the N2-B region in the 2q31-linked DCM family could identify no causative mutation (21) . However, because the N2-B region consists of about 1000 amino acids, only about 3% of the whole titin molecule, it may be needed to investigate the other regions. Indeed, during the preparation of this manuscript, the genomic organization of whole titin gene has been reported to consist of more than 360 exons (20) .
On the other hand, we have reported a titin mutation in a patient with hypertrophic cardiomyopathy (HCM) (22) , another form of hereditary cardiomyopathy, caused by mutations in the genes for sarcomeric proteins in the cardiac muscle (23) . The HCM-related titin mutation was found in the Z-line region of titin (22) . Titin forms a ternary complex with ␣-actinin and ␣-actin at the Z-line of striated muscles (24, 25) . The Z-line region of titin has seven tandem repeats in the middle of Z-line, called as Z-repeats (26) , and it has been reported that C-terminal region of ␣-actinin interacts with these titin Z-repeats (25, 27) . As assessed by yeast-two-hybrid (Y2H) assays, the Z-repeat 7 has strong ␣-actinin binding affinity, and each of the Z-repeat 1 to 3 has weak binding affinity. The titin mutation identified in the HCM patient was at the end of the Z-repeat 7 and showed an increased binding affinity to ␣-actinin by about 40% (22) . Titin is also known to bind to another Z-line component called as T-cap (28)/telethonin (29) , and it has been reported that T-cap/telethonin is phosphorylated by the titin kinase in vitro (30) and suggested to play a key role in sarcomere assembly.
It should be noted here that mutations in some sarcomeric proteins genes such as ␣-actin, ␤-myosin heavy chain, and troponin T genes cause DCM whereas different mutations in the same genes cause HCM (23) , suggesting that the abnormalities in sarcomeric proteins would express different clinical phenotypes depending on the mutations. However, it is not clear why and how the mutations in the same gene could cause different disease phenotypes. Then, it will be of interest to find a titin mutation in DCM and to investigate its functional alterations in comparison with the titin mutation reported in HCM (22) . We report here titin mutations found in Japanese patients with familial DCM and their functional changes in binding to other Z-line components, ␣-actinin or T-cap/telethonin. This is the first report showing that the titin mutations in DCM cause functional alterations in clearly different from or even opposite to that in HCM. In addition, the heart-specific N2-B region of titin gene was screened for mutation and two possible DCM-related mutations including a termination mutation were found in Japanese sporadic DCM patients. These observations strongly suggest that the titin gene is a novel disease gene for DCM.
MATERIALS AND METHODS
Cloning and sequencing of N2-B domain of genomic DNA for titin. The N2-B domain of human titin cDNA fragment (from bp 10321 to bp 13462 of X90568) was amplified from total cardiac RNA by using the reverse transcription (RT)-PCR method (31) . The following primers were used in the RT-PCR. LABF (5Ј-AGGATTGAACAAGAGATT-GAGATGG-3Ј) and LABR (5Ј-GTTTACGTTCCGGAAGTAATTTGCG-3Ј). The RT-PCR products were cloned into pCRII (Invitrogen) by the TA cloning method according to the manufacturer's instructions. After confirming the nucleotide sequence, the cloned cDNA fragment was cleaved by EcoRI digestion. The EcoRI restriction fragments were electrophoresed in an 0.8% agarose gel and extracted from the gel by using a kit (Geneclean II, BIO101). The gel purified DNA fragment was used as a probe for screening a human genomic library (EMBL 3 SP6/T7, Clontech). After hybridizing with labeled probes, we obtained two phage clones and extracted DNAs from the purified clones. The DNAs were digested by EcoRI and subcloned into pCU18 (Takara). The subclones containing the titin exons as assessed by Southern blot hybridization were sequenced by using multiple scanning primers to determine the intron/exon boundaries by the cycle sequencing method (Amersham).
Subjects. One hundred twenty genetically unrelated patients with DCM were chosen as subjects. Among them, apparent family histories of DCM consistent with autosomal dominant inheritance were observed in thirty-one cases. All the patients manifested with typical DCM phenotype as described previously (32) (33) (34) . These patients had been analyzed for mutations in the ␣-cardiac actin, desmin, dystrophin and lamin A/C genes and no mutations was found in any of them. Control subjects were two hundred and sixty unrelated healthy Japanese individuals selected at random. After acquiring informed consent, blood samples were obtained from each subject.
PCR-DCP and sequencing analysis. Genomic DNA extracted from peripheral blood of each panel was subjected to PCR under standard conditions by use of primer pairs specific to each region analyzed. Sequences of the primers used in the analysis are available upon request. PCR products from patients were searched for sequence variations by the PCR-DCP methods, as described previously (35) . When an abnormal DCP pattern was obtained, the PCR product was cloned by the TA cloning method into pCRII vector (Invitrogen), and several independent clones were sequenced on both strands to confirm the sequence variations.
amplified from total cardiac RNA by using the RT-PCR method. A normal cDNA fragment (corresponding to aa416 to aa748 that contains all Z-repeats 1 to 7) was obtained by using primers T1F (5Ј-GATCGAATTCGTGAAACAAGATGCTGACAAAA-3Ј, underlined sequences are added for cloning) and T7NR (5Ј-GATCGGATCCT-TGCGGCGGAAATGCGTTC-3Ј), while an equivalent mutant cDNA fragment having a C to T substitution on sense strand (double underlined sequences in T7NR and T7MR-2) was obtained by using primers T1F and T7MR-2 (5Ј-GATCGGATCCTTGCGACGGAAA-TGCGTTC-3Ј). These cDNAs were cloned into pCRII and confirmed for the sequences. The normal and mutant cDNA fragments were cleaved by EcoRI and BamHI to be subcloned into pAS2-1 vector (Matchmaker two-hybrid system 2, Clontech) to obtain the normal and mutant titin bait plasmids, respectively. The bait plasmids were used for transformation of Saccharomyces cerevisae (strain Y187) to obtain bait-bearing yeast clones.
Three different human ␣-actinin 2 cDNA fragments (ACTN2A-a; from bp2575 to bp2858 of M86406, corresponding aa802-aa894, ACTN2A-b; from bp2454 to bp2738, aa761-aa855, and ACTN2A-c; from bp2325 to bp2648, aa732-aa825) were amplified from human cardiac RNA by the RT-PCR method with primers, ACTN2A-aF (5Ј-GATCAGATCTTAGATCCCAACGGGCAAGG-3Ј) and ACTN2A-aR (5Ј-GATCAGATCTCACAGATCGCTCTCCCCG-3Ј), ACTN2A-bF (5Ј-GATCAGATCTCCTTCAACCACTTTGACAGG-3Ј) and ACTN2A-bR (5Ј-GATCAGATCTCAGGGCAGCTCCCGACGCA-3Ј), and ACTN2A-cF (5Ј-GATCAGATCTTCGCCAGAACCATCAATGAG-3Ј) and ACTN2A-cR (5Ј-GATCAGATCTCAGGTGTCAGCCGTCTCTCTA-3Ј), to be cloned into pACT2 vector to obtain the ACTN plasmids. Nucleotide sequences of these plasmids and orientations of inserts were confirmed by the sequencing analysis. The bait-bearing yeast clones were transformed with each ACTN plasmid.
A human full length T-cap/telethonin cDNA fragment (residues 11-514; EMBL accession number AJ000491) was also amplified from total cardiac RNA by using the RT-PCR method with primers TCAPNcoF (5Ј-CCATGGTGGCTACCTCAGAGCTGAGC-3Ј) and TCAPBamR (5Ј-GGATCCTCAGCCTCTCTGTGCTTCCTG-3Ј). The PCR fragments were cloned into pCRII for sequence confirmation. To obtain the bait plasmid, the T-cap/telethonin cDNA fragment was cleaved by digestion with NcoI and BamHI, gel-purified, and inserted into pAS2-1 vector.
Human titin Z1-Z2 cDNA fragments (residues 123-731; EMBL accession number NM_003319) and equivalent mutant cDNA fragments were also obtained by the RT-PCR method with primers TTN-NcoF (5Ј-CCATGGTGACAACTCAAGCACCGACG-3Ј) and TTN-BamR (5Ј-GGATCCAGGTACTTCTTCTTCACCTTGA-3Ј). The mutant cDNA fragment was obtained by combination of two PCR (36); one was with TTN-NcoF and TTN-54MR (5Ј-CTA-AAGGAGATCTGCATGCC-3Ј), and the other was with TTN-54MF (5Ј-GGCATGCAGATCTCCTTTAG-3Ј) and TTN-BamR. The normal and mutant titin cDNA fragments were cloned into pACT2 vector and the nucleotide sequences were confirmed. The T-cap/telethonin plasmid and titin Z1-Z2 domain plasmid were used for cotransformation of Saccharomyces cerevisae (strain Y187). Selection of transformants for the lacZ-reporter gene-activation assay was performed on selection agar plates lacking leucine and tryptophan. The transformants appeared after incubation for 4 -5 days at 30°C were tested by the filter assays for the ␤-galactosidase activity according to the manufacturer's instructions (Clontech). The ␤-galactosidase activity was also measured with -nitrophenyl ␤-Dgalactopyranoside (ONPG) as substrate in separate transformants, as described previously (22) .
RESULTS

Detection of Mutations in the Z-Line Region of Titin
The Z-line region coding exons of titin gene, from exon 2 to exon 16, were analyzed for sequence variations in Japanese patients with DCM. Three variations leading to amino acid replacement were found. One of them, Arg328Cys, was also found in healthy controls, indicating it is a polymorphism not related with DCM (data not shown).
In contrast, in the analysis of exon 14 corresponding to the Z-repeat 7 functioning as the major ␣-actinin binding domain, a 40-year-old male proband patient with familial DCM (JK109) showed an abnormal DCP pattern of PCR product (Fig. 1a) . This abnormal DCP pattern was inherited by his 16-year-old daughter, who also was affected with DCM, and was not found in 520 normal chromosomes, suggesting that it may be a DCM-associated mutation. An interesting clinical feature of these familial DCM patients was that both had manifested with cardiac arrhythmias (premature atrial or ventricular contraction and atrio-ventricular conduction block) before they developed DCM or congestive heart failure. Sequencing analysis revealed that this pattern was due to a C to T transition in codon 743, replacing a GCC (Ala) with GTC (Val) (Fig. 1b) . The Ala743Val mutation was located near the titin mutation reported in HCM, Arg740Leu, and the alanine at codon 743 was conserved in rabbit but not in chicken, as shown in Fig. 1c .
On the other hand, we found another abnormal DCP pattern in exon 3 from a 19-year-old female patient with DCM (JH318), whose father had died of DCM before (Fig. 2a) . This abnormal DCP pattern was not found in 520 normal chromosomes, implying that it may also be a disease-associated mutation. It was revealed by sequencing that this abnormal DCP pattern was due to a G to A transition in codon 54, replacing GTG (Val) with ATG (Met) (Fig. 2b) . The substitution at codon 54, Val54Met, was found at the evolutionary well conserved residue in the Z1 domain of titin (Fig. 2c) .
Decrease in Binding Affinity of Titin to Z-Line Components Due to the Mutations
The Ala743Val and Val54Met mutations were found in the biding domain of titin to ␣-actinin and T-cap/ telethonin, respectively, while the Arg328Cys polymorphism was located in the domain not known for binding to any Z-line proteins (Fig. 3a) . These observations suggested that two possible disease-related mutations might alter the function of titin via changing the binding affinity to the Z-line proteins, while the polymorphism might not.
To study the functional consequences of the Ala743Val replacement with regard to its binding to ␣-actinin, we performed Y2H assays. Wild-type or mutant titin bait plasmid (containing cDNA encoding 333 amino acids corresponding to all seven Z-repeats) was cotransformed with an activator plasmid containing ␣-actinin 2 cDNA. First, we tested colony lift filter assay for ␤-galactosidase (␤-gal) activity. Co-transformants of titin bait with ACTN2A-a plasmid (corresponding to aa802 to aa894 of ␣-actinin 2) appeared blue, while that with ACTN2A-b (aa761-aa855) or ACTN2A-c (aa732-aa825) plasmid did not show the ␤-gal activity. These data further confirmed that the C-terminal part of ␣-actinin was sufficient for binding to the Z-repeats of titin (25, 27) . Cotransformants containing normal or mutant titin plasmid in combination with ACTN2A-a plasmid appeared blue, and no visible difference was observed between them. To further investigate the relative strength of interactions between ␣-actinin and titin, we measured the ␤-gal activity of several independent transformants containing normal or mutant titin using ONPG as substrate. The assays showed that the corrected ␤-gal activity of normal titin (Ala at codon 743) colonies was 4.28 Ϯ 0.99, while that of mutant titin (Val at codon 743) colonies was 2.56 Ϯ 0.84, and the difference was statistically significant ( p ϭ 0.04) (Fig. 3b) . These data indicated that the affinity of titin Z-repeats to the C-terminal region of ␣-actinin was decreased by about 40% due to the Ala743Val mutation.
On the other hand, the effect of the Val54Met replacement on the binding to ⌻-cap/telethonin was tested also by using the Y2H assays. Full-length ⌻-cap/ telethonin bait plasmid was co-transformed with titin prey plasmid containing either mutant or wild type version of the Z1-Z2 domains. It was observed that the corrected ␤-gal activity of normal titin to T-cap/ telethonin interaction was 0.426 Ϯ 0.005, while that of the Val54Met mutant showed statistically significant less activity of 0.300 Ϯ 0.004 ( p Ͻ 0.0001) (Fig. 3c) . We concluded that the affinity of titin Z1-Z2 domain to the T-cap/telethonin was decreased to about 60% of normal by the Val54Met mutation.
Identification of Mutation in the N2-B Domain of Titin
The I-band region of titin is composed of two main segments: tandem immunoglobulin (Ig)-like domains and a segment rich in proline (P), glutamic acid (E), valine (V) and lysine (K) residues (so-called PEVK region) (19) . Both segments are expressed along with the relatively short hinge region, designated as N2 domains, in muscle type-specific manner in the striated muscles. In the cardiac muscle of mammalian species, N2-A and N2-B domains are co-expressed and join the tandem Ig domains with the PEVK region, while the skeletal muscles express only the N2-A domain (37) . The cardiac muscle- specific N2-B domain is encoded by a single exon of 2781 bp (20) , and the PCR-DCP analysis of overlapping fragments were performed by using several primer pairs to detect sequence variations in the DCM patients.
In the middle of the 5Ј-sided exon for the N2-B domain, a 45-year-old male patient (JH151), who manifested with severe heart failure and cardiac dilatation without any signs of skeletal muscle disease such as muscle weakness or elevated serum creatinine kinase level, showed an abnormal DCP pattern of PCR product (Fig. 4a) . Samples from family relatives of this patient were not available, but this abnormal DCP pattern was not found in more than 520 normal chromosomes, implying that it might not be a polymorphism. Sequencing analysis revealed that this abnormal pattern was due to a C to T transition in codon 4053, generating a stop codon (TAG) from CAG (Gln); Gln4053ter mutation (Fig. 4b) .
On the analysis of the 3Ј-sided exon, we found another abnormal DCP pattern in a 51-year-old male patient with DCM (JC141) (Fig. 4c) . This pattern again was not found in more than 520 normal chromosomes, and sequencing analysis revealed that it was due to a G to A transition in codon 4465 replacing AGT (Ser) with AAT(Asp); Ser4465Asp (Fig. 4d ). There were two other sequences variations leading to amino acid replace- ments, Arg4084Gln and Thr4215Pro, in the DCM patients, but they also were observed in the controls, hence considered to be polymorphisms (data not shown, Fig. 5 ).
DISCUSSION
We report here seven sequence variations leading to amino acid replacement in the titin gene from DCM patients, and three of them were polymorphisms also found in the unrelated healthy controls. The other four variations detected in four of one hundred and twenty DCM patients were not found in the healthy controls, suggesting that they were associated with DCM and might be the causative mutations. Two mutations in the Z-line region, Val54Met and Ala743Val, were both identified in familial DCM cases, while the family histories were not confirmed in the other two patients with mutations in the N2-B region that is known to be expressed only in the cardiac muscle. One of the N2-B mutations was the nonsense mutation, implying that a truncated titin molecule might be expressed in the heart of the patient. All these DCM-associated mutations were found in the heterozygous state; i.e., both normal and mutant titin may be expressed in the hearts of these patients. Although we could not confirm the expression of titin variants at the protein level due to lack of biopsied samples, these mutations may exert a dominant-negative effect, or haplo-insufficiency might cause functional alterations in the heart. Because three titin molecules form a Z-line complex with actinin and T-cap/telethonin, inclusion of mutant titin might change the function of the complex in the dominant-negative fashion. It should be noted here that a truncated titin molecule composed of only the Z-line region was reported to cause disorganization of sarcomere (38) , which may explain, in analogy, the causative role of the Gln4053ter mutation. Another possibility for the causative role of N2-B truncation is that it would loose binding to calpain 3, because calpain 3 is known to bind to N2-A region just after the N2-B region (20, 39) . It may be worth noting that mutations in calpain 3 gene cause limb-girdle type muscular dystrophy and most but not all of the calpain 3 mutants were reported to loose binding to titin N2-A region (40) .
The cytoarchitecture of myocytes plays an important role in maintaining cell structure and integrity of systolic function by proper force transmission. Because the Z-line plays a crucial role in the establishment and maintenance of cytoarchitecture, abnormality of cytoarchitectural proteins, especially in the Z-line and intercalated disk, was suggested to impair the force transmission to the adjacent sarcomere. In addition, the Z-line is important in establishing mechanical coupling of sarcomere and defects in function of the Z-linerelated proteins may lead to DCM. For example, mutations in the dystrophin complex cause membrane instability leading to heart failure (41). The potential importance of the cytoarchitecture in maintenance of cardiac performance is supported by that electronmicroscopic structural changes in cardiomyocytes and abnormal distributions of vinculin, desmin and tubulin were found in patients with DCM (42) . Reports of DCM phenotypes in mice deficient for MLP or ALP proteins by gene targeting also support this hypothesis (15, 16) .
By using Y2H assays, we demonstrated functional alterations induced by the mutations in the Z-line domain of titin. Due to the decreased binding affinity to ␣-actinin by Ala743Val mutation or that to T-cap/ telethonin by Val54Met, the sarcomere with mutant titin appears to lead systolic impairment. It is also presumed that the Ala743Val or Val54Met mutant titins may lead to impairment in the resistance to passive tension, and as a result, in the presence of mechanical stretch, mutation-prone cardiomyocytes would be more easily extended than the normal cardiomyocytes. Susceptibility to stretch or reduced resistance to passive tension could also be expected for a truncated titin mutant due to the nonsense mutation. In clear contrast, we have previously reported that the Arg740Leu mutation found in HCM increases the binding affinity to ␣-actinin (22); a functional change due to the titin mutation was opposite to that in DCM reported here. Although the molecular mechanism remains to be elucidated, the difference in phenotype, HCM or DCM, of titin mutations may be explained by the different changes in function, such as in binding affinity to other components in the Z-line.
On the other hand, it was argued that only one titin mutation reported in HCM made it difficult to discuss about the role of titin mutation in human cardiomyopathy (43) . Four possible titin mutations we identified in DCM patients here strongly suggest that titin mutations are involved in the development of cardiomyopa- thy, especially for DCM. On the other hand, we have also identified another mutation in the N2-B region, Ser3799Tyr, in two sister cases with familial HCM (Fig. 5 , details will be published elsewhere). We must wait for discussing the causative role of the titin N2-B region mutation in HCM unless we could confirm the linkage of the mutation with HCM in the family or demonstration of functional alterations. However, our observation implies that the titin mutation may also cause HCM, and this can be testable since the whole genomic organization of titin has now been revealed (20) .
In conclusion, we report here four potential mutations associated with DCM, one of which, Glu4053ter, may lead to a non-functional titin protein that is unable to span half-sarcomeres. For the other three replacements, it is more difficult to predict if they are indeed causative mutations. However, our data that these replacements are not present in more than 500 control chromosomes are in favor of a disease-associate role. Furthermore, two mutations in the Z-line region of titin found in familial DCM cases, Val54Met and Ala743Val, decreased the binding affinity of titin to T-cap/telethonin and ␣-actinin, respectively. These observations imply that titin mutations may lead to "loose sarcomere" and ultimately cause DCM phenotype in humans. Because we could identify mutations in two out of thirty-one familial DCM patients and two out of eighty-nine sporadic DCM cases by analyzing only about 7% of the whole titin gene, the titin mutation may be one of the major genetic etiologies of DCM at least in Japanese.
